Effect of 3'azido-2',3'-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats. 1994

N R Smyth, and M Bennett, and R M Gaskell, and C M McCracken, and C A Hart, and J L Howe
Department of Veterinary Clinical Science, University of Liverpool.

The compound 3'azido-2',3'-deoxythymidine (AZT) inhibits the replication of feline immunodeficiency virus (FIV) in cell culture, and treatment with the compound has been reported to induce some clinical improvement in some cases of feline FIV infection. In order to determine the effect of prophylactic treatment with AZT on experimental FIV infection, cats were treated with the compound at 0.2, 1.0, 5, 25 or 50 mg kg-1 day-1 for 29 days. One day after the treatment was started, they were inoculated with 150 cat infectious doses of FIV. All the cats became viraemic, seroconverted and developed lymphadenopathy, although the onset of each was delayed in the cats given higher doses of AZT. Anaemia developed in the cats given high doses of AZT. Virus re-isolated from the cats given 50 mg kg-1 day-1 was as susceptible to AZT in cell culture as the inoculated virus. Thus AZT is much less effective in cats than might have been expected from the results of in vitro studies.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002415 Cats The domestic cat, Felis catus, of the carnivore family FELIDAE, comprising over 30 different breeds. The domestic cat is descended primarily from the wild cat of Africa and extreme southwestern Asia. Though probably present in towns in Palestine as long ago as 7000 years, actual domestication occurred in Egypt about 4000 years ago. (From Walker's Mammals of the World, 6th ed, p801) Felis catus,Felis domesticus,Domestic Cats,Felis domestica,Felis sylvestris catus,Cat,Cat, Domestic,Cats, Domestic,Domestic Cat
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D016089 Immunodeficiency Virus, Feline A species of LENTIVIRUS, subgenus feline lentiviruses (LENTIVIRUSES, FELINE) isolated from cats with a chronic wasting syndrome, presumed to be immune deficiency. There are 3 strains: Petaluma (FIP-P), Oma (FIP-O) and Puma lentivirus (PLV). There is no antigenic relationship between FIV and HIV, nor does FIV grow in human T-cells. FIV,FTLV,Feline Immunodeficiency Virus,Feline T-Lymphotropic Lentivirus,Lentivirus, Puma,Puma lentivirus,Feline T-Lymphotropic Virus,Feline Immunodeficiency Viruses,Feline T Lymphotropic Lentivirus,Feline T Lymphotropic Virus,Lentivirus, Feline T-Lymphotropic,T-Lymphotropic Lentivirus, Feline,T-Lymphotropic Virus, Feline
D016181 Feline Acquired Immunodeficiency Syndrome Acquired defect of cellular immunity that occurs in cats infected with feline immunodeficiency virus (FIV) and in some cats infected with feline leukemia virus (FeLV). AIDS, Feline,FAIDS,Feline AIDS,Feline Acquired Immune Deficiency Syndrome,Feline Acquired Immuno-Deficiency Syndrome,Feline Acquired Immuno Deficiency Syndrome

Related Publications

N R Smyth, and M Bennett, and R M Gaskell, and C M McCracken, and C A Hart, and J L Howe
January 1991, Journal of virology,
N R Smyth, and M Bennett, and R M Gaskell, and C M McCracken, and C A Hart, and J L Howe
April 1988, Acta crystallographica. Section C, Crystal structure communications,
N R Smyth, and M Bennett, and R M Gaskell, and C M McCracken, and C A Hart, and J L Howe
May 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
N R Smyth, and M Bennett, and R M Gaskell, and C M McCracken, and C A Hart, and J L Howe
February 1990, AIDS research and human retroviruses,
N R Smyth, and M Bennett, and R M Gaskell, and C M McCracken, and C A Hart, and J L Howe
January 1989, Drug metabolism and disposition: the biological fate of chemicals,
N R Smyth, and M Bennett, and R M Gaskell, and C M McCracken, and C A Hart, and J L Howe
February 1999, Antimicrobial agents and chemotherapy,
N R Smyth, and M Bennett, and R M Gaskell, and C M McCracken, and C A Hart, and J L Howe
October 2000, Journal of virology,
N R Smyth, and M Bennett, and R M Gaskell, and C M McCracken, and C A Hart, and J L Howe
June 1998, Journal of virology,
N R Smyth, and M Bennett, and R M Gaskell, and C M McCracken, and C A Hart, and J L Howe
May 1994, Antimicrobial agents and chemotherapy,
N R Smyth, and M Bennett, and R M Gaskell, and C M McCracken, and C A Hart, and J L Howe
June 1989, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!